Kintor Pharmaceutical Ltd stock analysis
Want to see HK:9939 full AI Analyst Report?
Kintor Pharmaceutical Ltd (9939) Stock Price & Analysis
9939 Stock Chart & Stats
- Day’s Range
- HKD 1.37 - HKD 1.47
- 52-Week Range
- HKD 1.21 - HKD 4.70
- Previous Close
- HKD 1.38
- Volume
- N/A
- Average Volume (3M)
- 753.93K
- Market Cap
- HKD 675.74M
- Enterprise Value
- HKD 1.06B
- Total Cash (Recent Filing)
- HKD 31.79M
- Total Debt (Recent Filing)
- HKD 133.56M
- Price to Earnings (P/E)
- ―
- Beta
- 1.17
- Next Earnings
- Apr 01, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue Rebound
The sharp 2025 revenue rebound shows that the company is generating more commercial activity after weaker periods. If this improvement persists, a larger revenue base could support operating leverage, improve funding capacity, and provide a stronger platform for its marketed and pipeline therapies.
Narrowing Losses
Although the company remains unprofitable, materially narrower losses than in 2022–2023 indicate some improvement in financial performance. Continued progress could reduce the pace of capital consumption and improve the company’s ability to fund development and commercialization activities over time.
Moderate Leverage
Moderate leverage provides a more manageable capital structure than highly debt-funded biotech models. This may preserve some financial flexibility for development and commercialization investment, provided the company can eventually improve profitability and prevent further erosion of its equity base.
Bears Say
Persistent Unprofitability
Negative gross profit means the company has not yet demonstrated that its commercial activities can cover direct costs, while continuing operating and net losses deepen the challenge. Without durable margin improvement, revenue growth alone may not translate into sustainable earnings or self-funded expansion.
Ongoing Cash Burn
Persistent negative operating and free cash flow indicates that the business is not currently funding itself through operations. Continued cash burn can force reliance on external capital, potentially limiting development choices and creating ongoing financing pressure until cash generation improves.
Shrinking Equity Base
A shrinking equity base reflects cumulative value erosion from sustained losses and reduces the financial cushion available to absorb further setbacks. Strongly negative returns on equity also indicate that invested capital is not producing value, increasing the importance of a credible path to profitability.
Kintor Pharmaceutical Ltd News
Kintor completes year-long safety trial for whitening ingredient KT-939
Kintor Pharmaceutical Ltd ( ($HK:9939) ) has shared an announcement. Kintor Pharmaceutical announced the successful completion of a year-long human safety trial for KT-939, its in-house developed tyrosinase inhibitor designed
Kintor Advances KT-939 Cosmetic Raw Material With Strong Safety Data and China Registration Push
An update from Kintor Pharmaceutical Ltd ( ($HK:9939) ) is now available. Kintor Pharmaceutical reported positive interim data from a long-term human safety trial of KT-939, a new cosmetic whitening
9939 FAQ
What was Kintor Pharmaceutical Ltd’s price range in the past 12 months?
What is Kintor Pharmaceutical Ltd’s market cap?
When is Kintor Pharmaceutical Ltd’s upcoming earnings report date?
How were Kintor Pharmaceutical Ltd’s earnings last quarter?
Is Kintor Pharmaceutical Ltd overvalued?
Does Kintor Pharmaceutical Ltd pay dividends?
What is Kintor Pharmaceutical Ltd’s EPS estimate?
How many shares outstanding does Kintor Pharmaceutical Ltd have?
What happened to Kintor Pharmaceutical Ltd’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Kintor Pharmaceutical Ltd?
What is the TipRanks Smart Score and how is it calculated?
Kintor Pharmaceutical Ltd Stock Smart Score
Company Description
Kintor Pharmaceutical Ltd
Kintor Pharmaceutical Limited, a biotechnology firm in its clinical development phase, is dedicated to the discovery, advancement, and marketing of a diverse array of small molecule and biological therapies. The company primarily concentrates on androgen-receptor-related diseases that represent significant unmet medical needs, serving patients both in the People's Republic of China and globally. Its comprehensive pipeline of investigational products includes: Proxalutamide, a second-generation androgen receptor (AR) antagonist, being explored for the treatment of metastatic castration-resistant prostate cancer, AR-positive breast cancer, and COVID-19. Pyrilutamide, another AR antagonist, is under development for androgenetic alopecia (AGA) and acne vulgaris. An ALK-1 antibody targeting metastatic hepatocellular carcinoma (HCC) and various other solid tumors. GT20029, a topical AR-PROTAC compound, designed to address AGA and acne vulgaris. The dual-target antibody PD-L1/TGF-ß, intended for non-small cell lung cancer, biliary tract cancer, triple-negative breast cancer, and HPV-associated tumors. Detorsertib, which is being investigated for metastatic solid tumors such as breast cancer, prostate cancer, and HCC. A Hedgehog/SMO Inhibitor, an agent that blocks the hedgehog signal transduction pathway, aimed at treating blood cancer and basal-cell carcinoma. Founded in 2009, Kintor Pharmaceutical Limited is headquartered in Suzhou, People's Republic of China.
- Sector
- General
- Industry
- Biotechnology
- CEO
- Youzhi Tong
- Employees
- 122
- Website
- www.kintor.com.cn
- Address
- Suzhou Industrial Park, Suzhou, JS, 215123, CN
Kintor Pharmaceutical Ltd (9939) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 3 | 5 | 14 |
| Technical Analysis | 2 | 5 | 3 |
| Moving Averages | 1 | 0 | 11 |
